Data / Drug companies / Sun Pharmaceutical Industries, Inc.
Sun Pharmaceutical Industries, Inc.: 239 products in the FDA NDC directory, labeler code 62756
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sun Pharmaceutical Industries, Inc. (labeler code 62756) lists 239 products in the FDA National Drug Code Directory, covering 44 finished drugs by generic name. By type: 146 bulk ingredients, 87 prescription drugs. Its main marketing category is bulk ingredients. The newest product started marketing on July 28, 2026.
The request: Watch Sun Pharmaceutical Industries, Inc. (FDA labeler code 62756): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 62756
- Products in commercial distribution
- 239
- Packages
- 422
- Finished drugs by generic name
- 44
- Prescription products
- 87
- Over the counter products
- 5
- Controlled substance products
- Schedule III 11, Schedule IV 5, Schedule V 2
- Flagged as original packager
- 91 of 91 products that carry the flag
- Started marketing in the last 12 months
- 14
- Products with a marketing end date set
- 1
- Earliest marketing start
- February 9, 2006
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 146 | 61.1% |
| Generic drugs (ANDA) | 90 | 37.7% |
| New drug applications (NDA) | 2 | 0.8% |
| Drugs for further processing | 1 | 0.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 146 | 61.1% |
| Prescription drugs | 87 | 36.4% |
| Over the counter drugs | 5 | 2.1% |
| Drugs for further processing | 1 | 0.4% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 146 | 61.1% |
| Tablet, film coated | 20 | 8.4% |
| Tablet | 18 | 7.5% |
| Capsule | 15 | 6.3% |
| Injection, solution | 9 | 3.8% |
| Tablet, delayed release | 4 | 1.7% |
| Tablet, extended release | 4 | 1.7% |
| Injection, powder, lyophilized, for solution | 3 | 1.3% |
| Tablet, for suspension | 3 | 1.3% |
| Injectable, liposomal | 2 | 0.8% |
| Tablet, orally disintegrating | 2 | 0.8% |
| Suspension/ drops | 2 | 0.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sugammadex | 62756-079 | Injection, solution | Generic drugs (ANDA) | July 28, 2026 |
| Orlistat | 62756-047 | Powder | Bulk ingredients | July 8, 2026 |
| Liothyronine sodium | 62756-447 | Powder | Bulk ingredients | June 10, 2026 |
| Paliperidone palmitate | 62756-934 | Powder | Bulk ingredients | April 17, 2026 |
| Divalproex sodium process-ii | 62756-932 | Powder | Bulk ingredients | February 17, 2026 |
| Teriparatide | 62756-715 | Powder | Bulk ingredients | December 30, 2025 |
| Lanreotide acetate | 62756-929 | Powder | Bulk ingredients | December 10, 2025 |
| Liraglutide | 62756-927 | Powder | Bulk ingredients | December 10, 2025 |
| Bosutinib | 62756-721 | Powder | Bulk ingredients | December 10, 2025 |
| Alectinib hydrochloride | 62756-704 | Powder | Bulk ingredients | December 10, 2025 |
| Dasatinib | 62756-703 | Powder | Bulk ingredients | December 10, 2025 |
| Afatinib dimaleate | 62756-050 | Powder | Bulk ingredients | December 10, 2025 |
| Colestipol hydrochloride | 62756-930 | Powder | Bulk ingredients | November 26, 2025 |
| Ondansetron hydrochloride | 62756-109 | Powder | Bulk ingredients | November 21, 2025 |
| Clopidogrel bisulfate | 62756-965 | Powder | Bulk ingredients | March 31, 2025 |
| Desmopression acetate | 62756-940 | Powder | Bulk ingredients | March 31, 2025 |
| Irinotecan hydrochloride trihydrate | 62756-939 | Powder | Bulk ingredients | March 31, 2025 |
| Gemcitabine hydrochloride | 62756-807 | Powder | Bulk ingredients | March 31, 2025 |
| Nintedanib esylate | 62756-691 | Powder | Bulk ingredients | March 31, 2025 |
| Pentetreotide | 62756-685 | Powder | Bulk ingredients | March 31, 2025 |
| Pregabalin | 62756-441 | Powder | Bulk ingredients | March 31, 2025 |
| Risedronate sodium | 62756-255 | Powder | Bulk ingredients | March 31, 2025 |
| Linaclotide | 62756-154 | Powder | Bulk ingredients | March 31, 2025 |
| Bivalirudin | 62756-051 | Powder | Bulk ingredients | March 31, 2025 |
| Olopatadine hydrochloride | 62756-041 | Powder | Bulk ingredients | March 31, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.